$4.950
+0.829 (+16.75%)收盘时
YDES 资讯
YDES 事件
YD Bio Partners with EG BioMed to Launch Cancer Risk Assessment
YD Bio announced a strategic collaboration with EG BioMed, an affiliate of YD Bio, and digital health provider JoiiUp. The partnership integrates an AI cancer risk assessment, jointly developed by YD Bio and EG BioMed, into JoiiUp's JoiiSports app, expanding access to personalized health insights for corporate wellness programs and healthcare institutions. The assessment was developed in collaboration with three Taipei Medical University affiliated hospitals and validated using over 1,200 clinical records. JoiiUp supports the employee wellness programs of over 400 companies. Initial deployment is expected to focus on JoiiUp's existing corporate partner network. "This Assessment is the first step in building a comprehensive cancer management pathway spanning risk assessment, early detection, and precision medicine," said Ethan Shen, chairman and CEO of YD Bio.
YD Bio Ltd Trading Halted Due to Volatility
YD Bio Ltd trading halted, volatility trading pause
YD Bio Ltd Trading Halted Due to Volatility
YD Bio Ltd trading halted, volatility trading pause
YD Bio Aims for Conditional Clinical Milestone in Taiwan by 2027 for Glioblastoma Therapy
YD Bio highlighted the strategic roadmap shared by CEO Ethan Shen. YD Bio is building a comprehensive ecosystem that synchronizes diagnostic intelligence with advanced therapeutic execution. By integrating cancer detection technologies with late-stage dendritic cell immunotherapy programs, the company aims to create a cohesive cycle of data-informed therapy and disciplined clinical translation. YD Bio Ltd is connecting early cancer and aging detection programs with late-stage dendritic cell immunotherapy. By using diagnostic data to monitor and evaluate therapeutic responses, the Company creates a feedback loop that informs and accelerates clinical decision-making. By serving as an Official U.S. Agent for FDA submissions and successfully completing its first FDA IND filing, the company has embedded itself directly into the regulatory process. The company is targeting a conditional clinical pathway milestone in Taiwan by 2027 for its glioblastoma dendritic cell therapy.
YD Bio Enters Strategic Alliance Agreement with YC Biotech
YD Bio announced that its subsidiary YD Bio USA entered into a Master Strategic Alliance Agreement with YC Biotech on February 24, 2026. This partnership represents a pivotal advancement in the Company's mission, establishing YD Bio USA as the official strategic hub and exclusive U.S. Agent for regulatory applications to the U.S. Food and Drug Administration for YC Biotech's Contract Research Organization, CRO, clients in Asia. Under the terms of the Agreement, YD Bio USA will serve as YC Biotech's exclusive U.S. Agent and formal liaison with the FDA. In this role, YD Bio USA will manage official communications and correspondence with the FDA, represent sponsors in pre-IND and other formal regulatory meetings, provide high-level U.S. regulatory pathway strategies and positioning advice, and serve as compliance risk advisor. YD Bio USA will also coordinate FDA inspection readiness efforts to facilitate compliance with applicable U.S. regulatory requirements.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。